Recognizing Early Cardiac Amyloidosis in Older Adults With Atrial Fibrillation — Even When EF Looks Normal

If you or a loved one is 68 or older and living with “well-controlled” atrial fibrillation (AF), it’s natural to feel reassured—especially if your ejection fraction (EF) stays above 50% and routine tests look stable. But sometimes, subtle clues can point to something more complex beneath the surface: cardiac amyloidosis. Among the most important atrial fibrillation cardiac amyloidosis signs are unexplained fatigue, breathlessness that seems out of proportion to your AF burden, and lab or imaging results that don’t quite line up. This condition is rare but treatable—and catching it early makes a real difference in quality of life and longevity.

For adults over 50—especially those in their late 60s and beyond—heart disease isn’t always about blocked arteries or weakened pumping. It can also involve protein deposits quietly building up in heart tissue. One common misconception is that “preserved EF” means the heart muscle is healthy overall. Another is that fatigue or shortness of breath must simply be “part of aging” or “just from AF.” In fact, these symptoms—when paired with certain patterns—can signal an underlying cardiomyopathy that’s both diagnosable and increasingly manageable.

Why atrial fibrillation cardiac amyloidosis signs matter—and why they’re often overlooked

Cardiac amyloidosis occurs when misfolded proteins—most commonly transthyretin (TTR) or light-chain (AL)—accumulate in the heart muscle, making it stiff and less efficient at filling. In older adults, wild-type TTR amyloidosis (ATTR-CM) is far more common than AL, and it often appears after atrial fibrillation has already been diagnosed—sometimes by years. Because AF itself can cause fatigue and mild shortness of breath, clinicians may attribute new or worsening symptoms solely to rhythm issues—even when the AF is well-managed with medication or ablation.

What makes this especially tricky is that ATTR-CM frequently preserves left ventricular ejection fraction (LVEF) early on. Up to 70% of people with early ATTR-CM have LVEF ≥50%, which can delay suspicion. Yet structural changes are happening: the heart walls thicken subtly (often without hypertension), the atria enlarge, and electrical conduction slows—even before obvious heart failure develops.

This is where atrial fibrillation cardiac amyloidosis signs become so valuable. They’re not dramatic red flags—but quiet inconsistencies:

• Dyspnea that feels much worse than your documented AF burden would suggest (e.g., persistent breathlessness despite minimal AF episodes on Holter monitoring)
• Fatigue that doesn’t improve with rhythm control or rate management
• A low-voltage ECG pattern (QRS amplitude <5 mm in limb leads) despite normal or increased LV wall thickness on echo
• Discordant biomarker levels—like NT-proBNP >1,000 pg/mL while troponin and TTR levels remain only mildly elevated

These aren’t “definitive diagnoses,” but they’re compelling reasons to dig deeper.

How to assess for possible cardiac amyloidosis—beyond standard testing

Standard echocardiography is essential—but it has limits. In early ATTR-CM, echo may show only mild concentric thickening (LV wall thickness 12–14 mm), normal chamber sizes, and preserved EF. Clues that warrant further evaluation include:

• Strain imaging showing reduced global longitudinal strain (GLS), especially with an apical-sparing pattern (a classic “cherry-on-top” appearance on color-coded strain maps)
• Increased left atrial volume index (>34 mL/m²)
• Evidence of diastolic dysfunction (E/e′ ratio >14, prolonged deceleration time)

ECG findings are equally telling. While many assume a thick heart means high voltage, cardiac amyloidosis often causes low-voltage QRS complexes, even with normal or increased wall thickness—a paradox seen in roughly 40% of ATTR-CM cases. This mismatch alone raises suspicion.

Blood work adds another layer:

• NT-proBNP >1,000 pg/mL is highly suggestive—especially if rising over time without clear triggers like infection or uncontrolled hypertension
• Troponin I or T may be modestly elevated (e.g., >0.03 ng/mL) due to chronic myocardial stress
• Serum free light chains and immunofixation electrophoresis help rule out AL amyloidosis

But the gold-standard next step? Bone-avid tracer imaging—specifically technetium-99m pyrophosphate (PYP), DPD, or HMDP scans. These nuclear imaging tests detect amyloid deposits in the heart with >95% sensitivity and specificity for ATTR-CM when combined with absence of monoclonal protein. A grade 2–3 uptake on scan—plus no evidence of plasma cell disorder—is now considered diagnostic per international guidelines.

Who should consider this possibility—and when to ask questions

You don’t need to have all the signs above to benefit from discussion with your cardiologist. Consider exploring this possibility if you’re:

• Age 65 or older with long-standing or newly diagnosed AF
• Experiencing progressive fatigue or dyspnea not explained by other conditions (e.g., lung disease, anemia, deconditioning)
• Taking multiple heart medications (beta-blockers, digoxin, anticoagulants) with diminishing returns on symptom control
• Noted to have low-voltage ECG, thickened walls on echo, or elevated NT-proBNP (>600 pg/mL)

Importantly, family history matters—but not always in obvious ways. Wild-type ATTR-CM isn’t inherited, but hereditary forms (mutant TTR) are. If a parent or sibling was diagnosed with neuropathy, carpal tunnel syndrome, or heart failure before age 70, that’s worth mentioning—even if it wasn’t labeled “amyloidosis.”

Practical steps you can take—gently and proactively

Living well with AF—and staying alert to potential underlying conditions—starts with consistent, compassionate self-care. Here’s how you can support your heart health day to day:

Prioritize gentle movement. Short walks, seated stretching, or water-based exercise help maintain circulation and reduce fluid retention—without straining the heart. Aim for 20–30 minutes most days, adjusted to how you feel.

Stay hydrated—but mind sodium. Too little fluid can thicken blood and increase clot risk; too much salt can worsen stiffness and swelling. Work with your care team to find your personal balance—many find success with <2,000 mg sodium daily and consistent fluid intake (unless otherwise advised).

Monitor symptoms—not just numbers. Keep note of:

• When fatigue hits (morning vs. afternoon? after meals?)
• How many pillows you need to sleep comfortably
• Whether stairs or walking across the room feel harder than last month

Also pay attention to non-cardiac clues: unexplained weight loss, carpal tunnel surgery (especially bilateral), lumbar spinal stenosis, or gastrointestinal symptoms like early satiety or diarrhea—these can accompany systemic amyloidosis.

Tracking your blood pressure trends can help you and your doctor make better decisions. Consider keeping a daily log or using a monitoring tool to stay informed.

When to see your doctor:

• New or worsening shortness of breath at rest or with minimal activity
• Swelling in ankles, legs, or abdomen that doesn’t improve with elevation
• Persistent lightheadedness, near-fainting, or palpitations that feel different or more frequent
• Unexplained weight gain of 4+ pounds in 2 days or 5+ pounds in a week

These aren’t emergencies in every case—but they are invitations to pause, reflect, and seek clarity.

You’re not alone—and answers are within reach

Discovering that your “stable” AF might be linked to an underlying condition like cardiac amyloidosis can feel unsettling at first. But remember: awareness is the first step toward meaningful action. Today’s diagnostics—especially bone-avid tracer imaging—are more accessible and accurate than ever. And treatment options, including tafamidis and newer agents in clinical trials, are helping people live longer, more active lives with improved symptom control.

If you're unsure, talking to your doctor is always a good idea. Asking, “Could my fatigue or breathing changes be related to something beyond my AF?” opens the door to thoughtful, personalized evaluation—including looking for atrial fibrillation cardiac amyloidosis signs—with kindness and care.

FAQ

#### What are the earliest atrial fibrillation cardiac amyloidosis signs in older adults?

Early signs often include unexplained fatigue, disproportionate shortness of breath (even with minimal AF burden), low-voltage ECG despite normal or increased LV thickness, and discordant blood markers—such as high NT-proBNP with only mild troponin elevation. These signs are subtle but meaningful, especially in adults over 65.

#### Can atrial fibrillation cardiac amyloidosis signs appear even with normal ejection fraction?

Yes—absolutely. Up to 70% of people with early transthyretin cardiac amyloidosis (ATTR-CM) have preserved ejection fraction (≥50%). That’s why symptoms like fatigue and breathlessness, plus imaging or lab inconsistencies, matter more than EF alone.

#### Is there a blood test for atrial fibrillation cardiac amyloidosis signs?

No single blood test diagnoses cardiac amyloidosis—but key labs help guide evaluation. Elevated NT-proBNP (>1,000 pg/mL), modest troponin elevation, and normal serum free light chains (to rule out AL type) are important pieces. Confirmatory diagnosis relies on imaging—like bone-avid tracer scans—not bloodwork alone.

#### How common is cardiac amyloidosis in people over 65 with atrial fibrillation?

Studies suggest that among adults over 65 with AF and preserved EF, roughly 5–10% may have undiagnosed ATTR-CM—especially if they also have carpal tunnel syndrome, spinal stenosis, or a family history of neuropathy or heart failure. It’s underrecognized, but not rare.

#### Does having well-controlled atrial fibrillation mean my heart is healthy?

Not necessarily. Well-controlled AF means your rhythm or rate is managed—but it doesn’t rule out underlying structural changes like amyloid buildup, fibrosis, or diastolic stiffness. That’s why ongoing symptom assessment and periodic advanced testing (like strain echo or biomarkers) remain valuable parts of long-term care.